For a biosimilar to be approved as an interchangeable biosimilar, it must produce the same effects in a patient when substituted for the originator product without any additional risks. If a biosimilar receives an interchangeability designation, it can be substituted at the pharmacy without the intervention of the prescribing physician. The specific data requirements to receive regulatory approval for interchangeability are still being determined.